Alternative splicing (AS) plays a significant role in the hallmarks of cancer and can provide
neoantigens for immunotherapy. Here, we summarize recent advances in immune system associated
tumor specific-antigens (TSAs) produced by AS. We further discuss the regulating mechanisms
involved in AS-mediated innate and adaptive immune responses and the anti-tumoral and protumoral
roles in different types of cancer. For example, ULBP1_RI, MLL5Δ21spe, NKp44-1Δ5,
MHC-IΔ7, CD200SΔ1, 2, PVR α/β/γ/δ and IL-33 variants 1/2/3 act as regulators in solid tumors and
IPAK4-L and, FOXP1ΔN100 exhibit functions in hematological cancers.